Revolution Medicines
Presence
Revolution Medicines is one of the...
Revolution Medicines is a company listed under the stock ticker RVMD (US).
Acquisition, funding and merger involving Revolution Medicines.
- Revolution Medicines has acquired Eqrx (posted on November 10 2023).
Executives
View the org chart displaying its 37 main executives
Most searched biographies at Revolution Medicines
- Mark Goldsmith, President, Chief Executive Officer and Board Chair...
- Thilo Schroeder, Director
- Sushil Patel, Director
Create your alert
to follow the executive moves at Revolution Medicines.
Pharmaceuticals
Revolution Medicines has 1,861 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- MedMen has filed for bankruptcy protection (posted on April 28 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Revolution Medicines
- Press Releases | Revolution Medicines
- Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition | Revolution Medicines
- Revolution Medicines Completes Acquisition of EQRx | Revolution Medicines
- Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress | Revolution Medicines
- Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023 | Revolution Medicines
- Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc. | Revolution Medicines
- Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236 | Revolution Medicines
- Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast | Revolution Medicines, Inc.
- Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting | Revolution Medicines, Inc.
- Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor | Revolution Medicines, Inc.
- View more press releases Close
Social media about Revolution Medicines
- Revolution Medicines on Wikipedia, Google News & Yahoo Finance
- Revolution Medicines on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Mark Goldsmith 
Call Revolution Medicines at +1 415...
